Meeting
2024 ASCO Annual Meeting
Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).
Authors
Christian Grommes
Memorial Sloan Kettering Cancer Center, New York, NY
Christian Grommes , Han W. Tun , Adolfo de la Fuente Burguera , Anna Dabrowska-Iwanicka , Lucia Regales , Wanying Zhao , Dora Ferrari , Meaghan Fowles , Maureen E Lane , Catherine Wang , Reinhard W. Von Roemeling , Michal Taszner , Christopher D'angelo , Grzegorz S. Nowakowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Non-Glioma
Clinical Trial Registration Number
NCT03328078
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2087)
DOI
10.1200/JCO.2024.42.16_suppl.2087
Abstract #
2087
Poster Bd #
386
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe
Poster
2024 ASCO Annual Meeting
A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.
First Author: Elise A. Chong
Poster
2018 ASCO Annual Meeting
The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).
First Author: Paul A. Hamlin
Poster
2013 ASCO Annual Meeting
An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.
First Author: Gilles A. Salles